Patrick M. Forde
Led CheckMate 816, which established neoadjuvant chemo-immunotherapy for resectable lung cancer.
Pioneered neoadjuvant PD-1 blockade in resectable NSCLC (2018 NEJM pilot) and led the CheckMate 816 phase 3; also leads mesothelioma trials.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant PD-1 blockade in resectable lung cancer | New England Journal of Medicine | 2018 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer | New England Journal of Medicine | 2022 |
Pages like this
not linked directly; found by shared links- PersonJulie R. Brahmer
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Mesothelioma, Nivolumab.
- PersonSuzanne L. Topalian
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Nivolumab, PD-1, Non-small-cell lung cancer.
- PersonShun Lu
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, PD-1, Non-small-cell lung cancer.
- TrialCheckMate 141
- InstitutionLaura and Isaac Perlmutter Cancer Center at NYU Langone Health
Shares Nivolumab, PD-1, Non-small-cell lung cancer.
- PersonTasuku Honjo
Shares Nivolumab, PD-1, Non-small-cell lung cancer.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares Nivolumab, PD-1, Non-small-cell lung cancer.
- PersonSolange Peters
Shares Mesothelioma, Nivolumab, Non-small-cell lung cancer.